Literature DB >> 6201741

Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.

H A Liebman, B C Furie, M J Tong, R A Blanchard, K J Lo, S D Lee, M S Coleman, B Furie.   

Abstract

We detected des-gamma-carboxy prothrombin, an abnormal prothrombin, in the serum of 69 of 76 patients (91 per cent) with biopsy-confirmed hepatocellular carcinoma (the mean level of the abnormal prothrombin was 900 ng per milliliter). In contrast, levels of the abnormal prothrombin were low in patients with chronic active hepatitis (mean, 10 ng per milliliter) or metastatic carcinoma involving the liver (mean, 42 ng per milliliter), and undetectable in normal subjects. In five patients treated with vitamin K there was no reduction in abnormal prothrombin, indicating that its presence was not due to vitamin K deficiency. Surgical resection of tumors in two patients and chemotherapy in one patient markedly reduced abnormal-prothrombin concentrations, which later increased with recurrence of disease. Serum alpha-fetoprotein levels correlated poorly with abnormal-prothrombin levels. Together, the assay for abnormal prothrombin and the alpha-fetoprotein assay identified 64 of 76 patients with hepatoma (84 per cent). Abnormal prothrombin may be useful in the laboratory diagnosis of primary hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201741     DOI: 10.1056/NEJM198405313102204

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  125 in total

1.  PIVKA-II concentrations in patients with cystic fibrosis.

Authors:  E A Cornelissen; A F van Lieburg; C G van Oostrom; L Monnens
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

2.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Levels of plasma des-gamma-carboxy protein C and prothrombin in patients with liver diseases.

Authors:  Xiao-Fan He; Zhi-Bin Wen; Min-Juan Liu; Hui Zhang; Qun Li; Shi-Lin He
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

4.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

5.  Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma.

Authors:  R Kuromatsu; M Tanaka; Y Shimauchi; M Shimada; K Tanikawa; K Watanabe; T Yokoo
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

6.  Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.

Authors:  A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

Review 7.  Vitamin K and hepatocellular carcinoma: The basic and clinic.

Authors:  Xia Jinghe; Toshihiko Mizuta; Iwata Ozaki
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

8.  Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.

Authors:  Y Kawaguchi
Journal:  Jpn J Surg       Date:  1989-05

9.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

Review 10.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.